Table 2. Patients’ Characteristics... | American Society of Hematology

Table 2.

Patients’ Characteristics According to the Cord Blood Donor

Characteristics	Related (N = 42)	Unrelated (N = 60)	P^†
Median age (yr) range	5.5 (1.7-14)	5.5 (0.2-15)
<6/≥6	24/18	36/24	.64
Median weight (kg) range	19.5 (10-46)	20.0 (4.4-83)
<20/≥20	21/21	28/32	.63
Gender
Male	25	33	.70
Female	17	27
Diagnosis and status
ALL	30	40	.67
Poor risk	15	12
Good risk	15	28	.14
AML	12	20
Poor risk	3	6
Good risk	9	14	1.0
CMV serology
Negative	20	25	.69
Positive	22	34
ABO compatibility
Matched	31	27	.005
Mismatched	11	33
HLA disparities^*
Identical	30	6	.0006
1 difference	1	27
2 differences	3	22
3 differences	7	4
4 differences	1	1
Median no. of nucleated cells collected (10⁷)/kg of recipient (range)	4.0 (1.0-12.2)	5.0 (1.5-46.5)	.04
Median no. of nucleated cells infused (10⁷)/kg of recipient (range)	3.2 (0.7-10)	4.4 (0.9-36)	.30
Conditioning
TBI-containing regimens	22	34	.69
Chemotherapy-based regimens	20	26
ALG/ATG or monoclonal antibody	10	50	<.0001
GVHD prophylaxis
CsA	20	5	<.0001
CsA + steroid	3	41
CsA + MTX	13	5
CsA + MTX + steroid	2	3
CsA ± steroid ± ATG/ALG or Mab	4	4
FK506 + MTX	—	2

Characteristics	Related (N = 42)	Unrelated (N = 60)	P^†
Median age (yr) range	5.5 (1.7-14)	5.5 (0.2-15)
<6/≥6	24/18	36/24	.64
Median weight (kg) range	19.5 (10-46)	20.0 (4.4-83)
<20/≥20	21/21	28/32	.63
Gender
Male	25	33	.70
Female	17	27
Diagnosis and status
ALL	30	40	.67
Poor risk	15	12
Good risk	15	28	.14
AML	12	20
Poor risk	3	6
Good risk	9	14	1.0
CMV serology
Negative	20	25	.69
Positive	22	34
ABO compatibility
Matched	31	27	.005
Mismatched	11	33
HLA disparities^*
Identical	30	6	.0006
1 difference	1	27
2 differences	3	22
3 differences	7	4
4 differences	1	1
Median no. of nucleated cells collected (10⁷)/kg of recipient (range)	4.0 (1.0-12.2)	5.0 (1.5-46.5)	.04
Median no. of nucleated cells infused (10⁷)/kg of recipient (range)	3.2 (0.7-10)	4.4 (0.9-36)	.30
Conditioning
TBI-containing regimens	22	34	.69
Chemotherapy-based regimens	20	26
ALG/ATG or monoclonal antibody	10	50	<.0001
GVHD prophylaxis
CsA	20	5	<.0001
CsA + steroid	3	41
CsA + MTX	13	5
CsA + MTX + steroid	2	3
CsA ± steroid ± ATG/ALG or Mab	4	4
FK506 + MTX	—	2

HLA disparities were defined by using serological and low resolution typing for A, B locus, and DRB1 in related CBT and high resolution DRB1 typing for unrelated CBT.

†

Fisher’s test was used for categorical variables and Kruskal-Wallis test for noncategorical variables.

View Large

This Feature Is Available To Subscribers Only